Ventyx Biosciences Announces $27 Million Strategic Investment from Sanofi
WEB20 hours ago · Sanofi to receive an exclusive right of first negotiation for Ventyx’s CNS-penetrant NLRP3 inhibitor VTX3232SAN DIEGO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX ...
Ventyx Biosciences Announces $27 Million Strategic
WEB20 hours ago · Sanofi to receive an exclusive right of first negotiation for Ventyx’s CNS-penetrant NLRP3 inhibitor VTX3232. September 23, 2024 08:00 ET | Source: Ventyx Biosciences, Inc.
Sanofi makes $27M equity investment in Ventyx
WEB17 hours ago · Ventyx Biosciences Sanofi inflammatory diseases equity investment. After a series of trials and tribulations, Ventyx Biosciences has received a $27 million boost from Sanofi, money that is ...
Sanofi gains exclusivity rights to Ventyx’s CNS-penetrant drug in …
WEB14 hours ago · VTYX. Sanofi will gain exclusivity rights to Ventyx Biosciences’ CNS-penetrant candidate VTX3232 as part of a $27m deal. Under the terms of the agreement, Sanofi will buy 70,601 shares of Ventyx ...
Ventyx Biosciences Announces $27 Million Strategic Investment from Sanofi
WEB58 minutes ago · SAN DIEGO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Sanofi has agreed to make a $27 million strategic ...
Ventyx Biosciences Announces $27 Million Strategic Investment from Sanofi
WEB1 day ago · Sanofi to receive an exclusive right of first negotiation for Ventyx’s CNS-penetrant NLRP3 inhibitor VTX3232. SAN DIEGO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases …
Ventyx Biosciences Shares Rise Premarket on Sanofi Investment
WEB19 hours ago · Ventyx said Sanofi is buying 70,601 Series A non-voting convertible preferred shares, each convertible into 100 common shares at $3.82 each, a 66% premium to Friday's closing price of $2.30.
Sanofi Injects $27M In Neurology Drug Developer Ventyx Biosciences
WEB17 hours ago · Sanofi invests $27 million in Ventyx Biosciences at $3.8243 per share. The investment will fund VTX3232 trials for Parkinson's disease. Get Our Top Trade Ideas Delivered Daily - 65% Off Now
Ventyx stock climbs 8% on $27M Sanofi investment
WEBS hares of Ventyx Biosciences (NASDAQ: VTYX) jumped 8% in morning trading Monday on news that Sanofi (NASDAQ: SNY) has made a $27M strategic investment in the company in exchange for a right of ...
Ventyx Biosciences Receives $27M Investment from Sanofi
WEB1 day ago · Ventyx Biosciences, Inc. announced that Sanofi has agreed to make a $27 million strategic investment in the Company at an as-converted price of $3.8243 per share of common stock, pursuant to which Sanofi will purchase 70,601 of the Company’s Series A non-voting convertible preferred stock, each share of which is initially convertible into 100 shares of common stock. The closing of the ...
- Some results have been removed